PMID- 27801319
OWN - NLM
STAT- MEDLINE
DCOM- 20180320
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 37
IP  - 10
DP  - 2016 Oct 14
TI  - [Analysis of the impact of decitabine treatment cycles on efficacy and safety in 
      patients of myelodysplastic syndrome-refractory anemia with excess blasts].
PG  - 870-875
LID - 10.3760/cma.j.issn.0253-2727.2016.10.011 [doi]
AB  - Objective: To explore the impact of decitabine treatment cycles on efficacy and 
      adverse events(AEs)in patients of myelodysplastic syndrome-refractory anemia with 
      excess blasts(MDSRAEB). Methods: A total of fifty-six patients with MDS-RAEB who 
      received decitabine 20 mg.m(-2).d(-1)by IV infusion daily for 5 consecutive days 
      every 4 weeks at a single institute in China were enrolled from December 2008 to 
      March 2016. Their clinical features, efficacy, predictors of efficacy and AEs 
      were analyzed retrospectively. Results: Of the 56 patients enrolled, 25 cases 
      were MDS- RAEB1, another 31 were MDS-RAEB2. A median of 3 cycles(range, 1-15 
      cycles)were delivered. The overall response rate was 67.9%(10 complete responses, 
      8 marrow complete responses without hematologic improvement, 17 marrow complete 
      responses with hematologic improvements, and 3 hematologic improvements). With a 
      median follow-up duration of 7.9(1.0-56.3)months, the median overall survival was 
      21.1(95% CI 16.0- 26.1)months. Compared with RAEB-2, RAEB-1 predicted higher 
      overall response rates in a multivariate analysis. Of the 38 patients who 
      experienced clinical responses, initial responses were detected by the end of two 
      cycles in 37 patients. Twenty- five of the 38 patients who experienced clinical 
      responses had their best response within the first two cycles, and 37 cases of 
      the patients achieved best response by the end of fourth cycles. Grade 3 or 4 
      cytopenia and infection were the most prevalent AEs, which occurred frequently in 
      the early courses and decreased later, and other non- hematologic AEs were rare. 
      Conclusion: Decitabine treatment was favorable in patients with MDS- RAEB. In 
      most of the cases, initial responses were observed within 2 cycles, and best 
      response was achieved by the end of 4 th cycles. The most common AEs were grade 3 
      or 4 cytopenia and infection, which were observed frequently in first 2 cycles 
      and decreased later as objective response were achieved.
FAU - Luo, X P
AU  - Luo XP
AD  - Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key 
      Laboratory of Experimental Hematology, Tianjin 300020, China.
FAU - Xu, Z F
AU  - Xu ZF
FAU - Qin, T J
AU  - Qin TJ
FAU - Zhang, Y
AU  - Zhang Y
FAU - Zhang, H L
AU  - Zhang HL
FAU - Fang, L W
AU  - Fang LW
FAU - Pan, L J
AU  - Pan LJ
FAU - Hu, N B
AU  - Hu NB
FAU - Qu, S Q
AU  - Qu SQ
FAU - Li, B
AU  - Li B
FAU - Xiao, Z J
AU  - Xiao ZJ
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - *Anemia, Refractory, with Excess of Blasts
MH  - Azacitidine/analogs & derivatives
MH  - Blood Cell Count
MH  - China
MH  - Decitabine
MH  - Humans
MH  - Pancytopenia
MH  - Prevalence
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC7364885
EDAT- 2016/11/02 06:00
MHDA- 2018/03/21 06:00
PMCR- 2016/10/01
CRDT- 2016/11/02 06:00
PHST- 2016/11/02 06:00 [pubmed]
PHST- 2018/03/21 06:00 [medline]
PHST- 2016/11/02 06:00 [entrez]
PHST- 2016/10/01 00:00 [pmc-release]
AID - cjh-37-10-870 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2016.10.011 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):870-875. doi: 
      10.3760/cma.j.issn.0253-2727.2016.10.011.